ReviewCurrent allergy and asthma reports2013
Immunotherapy preparation guidelines, rules, and regulation.
Review in Current allergy and asthma reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Novel Sensitive, Two-site ELISA for the Quantification of Der f 1 Using Monoclonal Antibodies.Allergy, asthma & immunology research · 2021Article
- Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2017Review
- Proteomics for Allergy: from Proteins to the Patients.Current allergy and asthma reports · 2016Review
- Standardization and Regulation of Allergen Products in the European Union.Current allergy and asthma reports · 2016Review
- Control Process for Manufacturing and Standardization of Allergenic Molecules.Current allergy and asthma reports · 2015Review
- Immunotherapy in allergy and cellular tests: state of art.Human vaccines & immunotherapeutics · 2014Review
- Adherence with allergen immunotherapy labeling guidelines.The journal of allergy and clinical immunology. In practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen immunotherapy has been used to treat allergic diseases for more than 100 years. In the U.S., the preparation of diagnostic and therapeutic extracts requires the cooperation of the extract manufacturer, who provides the individual allergen concentrates, and the practicing physician who formulates, dilutes, and administers the final patient-specific treatment extract. The guidelines, rules, and regulations for these activities have been established and continue to be developed as progress is made. The molecular characterization and standardization of allergenic extracts has allowed for improvements in defining the potency of these products. In turn, these advances have led to improved dosing regimens and formulation practices. This review will describe in detail some of these interactions and will identify issues that require more attention.
Indexed as
Identifiers
23722699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.